Traws Pharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Traws Pharma sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Traws Pharma: 25 sponsored US clinical trials, none currently recruiting.
Traws Pharma sponsors 25 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 22 completed. 4 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelodysplastic Syndrome, with 3 trials.
Top-decile sponsor footprint
Traws Pharma ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
25 total, page 1 of 1
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
NCT02562443
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
NCT02168725
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
NCT02030639
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
NCT02107235
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
NCT01926587
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
NCT01928537
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
NCT01904682
Oral Rigosertib for Squamous Cell Carcinoma
NCT01807546
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
NCT01584531
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
NCT01360853
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
NCT01241500
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
NCT01168011
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
NCT01167166
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
NCT01165905
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
NCT01048619
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
NCT01049113
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
NCT00906334
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
NCT00856791
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
NCT00854945
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
NCT01125891
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
NCT00854646
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
NCT00861783
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
NCT00861328
Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
NCT01538537
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
NCT01538563
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 5 |
| Phase 3 | 4 |
Therapeutic Areas
How the Traws Pharma early-phase archive is shaped
25 indexed studies, none listed as recruiting (0% open); 22 completed (88%).
Phase mix: 4 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Myelodysplastic Syndrome (3 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Traws Pharma: archived-pipeline peers nationwide
Peers matched on 25 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Traws Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 archived trials
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Traws Pharma page
25 registered trials is a research-attention snapshot, not an endorsement of Traws Pharma or any single study.
- None of Traws Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Myelodysplastic Syndrome is the condition Traws Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelodysplastic Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Traws Pharma pipeline card: 25 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.